For many patients, the first signs of Alzheimer’s do not immediately lead to clear answers. These early changes often raise questions well before a diagnosis is established. Clinicians are often tasked with guiding next steps, yet the path to answers is not always straightforward.
In many cases, the initial evaluation provides limited insight. Subtle symptoms may be attributed to normal aging or stress. Early cognitive testing may be inconclusive. Patients and their caregivers may be asked to monitor changes over time, even as new concerns emerge. Clinicians work to interpret complex presentations without the full picture. The result is a prolonged period of diagnostic uncertainty and delayed decision-making.
This experience reflects the complexity of evaluating a condition that can be difficult to detect, especially in its early stages. Alzheimer’s has historically been diagnosed through cognitive testing and the exclusion of other causes. Symptoms often overlap with depression, sleep disorders, medication effects, vascular changes, and normal aging. Evaluations may span multiple providers and settings, leading to fragmented information and inconsistent access to advanced diagnostic tools. Together, these factors contribute to a persistent diagnostic confidence gap.
The field is now entering a new era, one increasingly defined by greater precision. As the landscape of Alzheimer’s care evolves, biomarker-supported approaches are becoming more common, and advanced imaging technologies such as PET scans can help reveal underlying pathology. Clinicians are increasingly integrating cognitive testing, imaging, and biomarker insights into a more cohesive understanding of each patient’s condition.
This is especially critical when answers are not immediately clear. In moments of diagnostic uncertainty, access to tools that provide more definitive insights can help distinguish Alzheimer’s disease from other causes of cognitive decline and enable more precise and timely clinical decisions.
Clarity matters because it shapes what comes next. As new therapies emerge, diagnostic confidence is becoming foundational to determining appropriate care pathways, including treatment eligibility and clinical trial participation. When clinicians can better understand the underlying biology of disease, they are better equipped to guide timely, informed decisions. More definitive answers help clinicians guide patients and families with greater clarity and confidence.
At GE HealthCare, we see this transformation as an important step forward and are focused on advancing diagnostic excellence and innovation in neurodegenerative disease, connecting imaging, data, and molecular insights to support more informed clinical decisions.
This includes advanced imaging equipment, digital solutions, and molecular imaging technologies, as well as radiopharmaceuticals such as Vizamyl™ (flutemetamol F 18 injection), an amyloid PET imaging agent that detects the extent and location of amyloid pathology in the brain.
Together, these solutions are designed to deliver more consistent, high-quality imaging and more definitive insights, helping clinicians better understand disease biology and make more confident decisions.
Expanding access to these capabilities, and integrating them into clinical workflows, remains equally important to ensure the right insights are available at the right point in the patient journey. This includes continued investment in infrastructure, clinical education, and broader access across care settings.
Ending the wait for answers is more than an aspiration. It reflects a broader shift toward reducing diagnostic uncertainty and enabling earlier, more informed clinical decision-making, and helping guide the right next steps for patients at the right time.
Vizamyl Important Safety Information
PRODUCT INDICATIONS AND USE
VIZAMYL™ (flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
- Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline
- Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products.
CONTRAINDICATIONS: VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80.
ADVERSE REACTIONS: The most commonly reported adverse reactions in clinical trials were flushing (2 %), increased blood pressure (2 %), headache (1 %), nausea and dizziness (1 %). Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Prior to VIZAMYL administration, please read the full Prescribing Information at gehealthcare.com/vizamyl-pi.
© 2026 GE HealthCare
Vizamyl is a trademark of GE HealthCare.
GE is a trademark of General Electric Company used under trademark license.
June 2026 | JB13960US
